A Stock Recent News

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent will release financial results for the fourth quarter of fiscal year 2024 on Nov. 25.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET. CEO Padraig McDonnell, CFO Bob McMahon, and other senior business leaders will present information regarding Agilent's strategy, businesses, and long-term financial outlook. The event will conclude with a Q&A session. This in-person event is by invitation only, but a live webcast will be accessible through Agilent's Investor Rel.

MIAMI--(BUSINESS WIRE)-- #Acquisition--H.I.G. Capital sold its portfolio company, BIOVECTRA Inc., to Agilent Technologies, Inc. (NYSE: A) for a purchase price of $925 million.

Agilent (A) reported earnings 30 days ago. What's next for the stock?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tec.

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields.

DENVER, CO / ACCESSWIRE / August 30, 2024 / On August 30, 2024, the Clough Global Equity Fund (NYSE American:GLQ) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0603 per share to shareholders of record at the close of business on August 16, 2024. The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder.

Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent acquisitions and divestitures show mixed results, with potential for technological enhancement but concerns about fit in the portfolio. Despite challenges in the pharma market, Agilent's diversified revenue streams and potential for growth in key areas make it a 'Buy' with a target price of $160 per share.